Objectives: The aim of this study is to investigate the role of peroxisome proliferator-activated receptor-gamma isoform (PPARg), in trigeminal neuropathic pain utilizing a novel mouse trigeminal inflammatory compression (TIC) injury model.
T rigeminal neuropathic pain is an orofacial pain condition characterized by continuous aching and burning sensation caused by trigeminal nerve damage. 1 Dental procedures or trauma can cause trigeminal peripheral nerve injury and inflammation, but in some cases, the cause is unknown. Clinicians most often treat this continuous trigeminal neuropathic pain with anticonvulsants and antidepressants, alone or in combination, which yields variable treatment responses. [2] [3] [4] [5] Therefore, there is a need for discovery of new drug targets.
The goal of the present studies was to investigate the potential for utilizing the clinically used thiazolidinedione pioglitazone (PIO), which reportedly decreases microglial activation and certain cytokines such as tumor necrosis factor-a (TNF-a) and interleukin 6 (IL-6). 6, 7 Thiazolidinediones target peroxisome proliferator-activated receptor (PPAR). PPAR is a nuclear receptor with 3 isoforms: a, b/d, and g. 8 PPAR is widely expressed in adipose, liver, cardiac, endometrial stromal cells, immune cells, neurons, and glia of the peripheral and central nervous system. [9] [10] [11] [12] [13] [14] [15] [16] [17] After ligand activation, the PPAR transcription factors of the nuclear hormone receptor superfamily play a major regulatory role in energy homeostasis and metabolic function. 18 These receptors form a heterodimer with retinoid X receptor controlling gene expression of PPAR response elements on DNA. 8, [19] [20] [21] In particular, the activation of PPARg has been shown to have multiple downstream effects.
PPARg is activated by endogenous lipids or by thiazolidinediones, such as rosiglitazone and PIO, which are FDA approved for the treatment of type 2 diabetes. These agonists have been shown to regulate fatty acid metabolism. 19, 22, 23 However, more recent studies suggest PPARg activation plays a role in another major pathway that suppresses neuroinflammatory mediators, such as NF-kB (nuclear factor k-light-chain-enhancer of activated B cells, thereby decreasing microglial activation, as well as TNF-a and IL-6. [6] [7] [8] 24 In addition to a reduction in paw edema after capsaicin injection, PPARg activation also reduces mechanical allodynia and thermal hyperalgesia in the sciatic nerve injury animal models. 6, 15, [25] [26] [27] [28] Furthermore, PPARg has been shown to be upregulated in Schwann cells after nerve injury. 29, 30 Other studies have found that PPARg in the retina is upregulated within 3 days after an optic nerve injury in a mouse and then returns to basal levels by day 14. 31 Although PPARg activation clearly is implicated in a decrease of specific types of neuropathic and inflammatory pain, the effects of PPARg activation on trigeminal pain have not been studied. Although Moreno et al 32 reported evidence of PPAR in the trigeminal nucleus, no one has explored the function of this receptor in the brainstem spinal trigeminal nucleus (spV). 3, 33 The spV consists of trigeminal nociceptive sensory nerve primary endings and second order system neurons that send information about painful stimulation to the thalamus by the trigeminothalamic pathway that then transmits the signals to the head/ neck/facial region of the sensory cortex (layer IV). 3, 33, 34 The aim of this study is to determine the role of PPARg in trigeminal neuropathic pain utilizing our novel mouse trigeminal inflammatory compression (TIC) injury model. 35 Our findings are that (1) the immunoreactivity for PPARg is increased in spVc at 3 weeks in mice with TIC injury; (2) PIO attenuates trigeminal TIC nerve injury-related pain dependent on PPARg activation. We evaluated: (1) PPARg immunoreactivity in the spV with/without TIC injury; (2) systemic administration of PIO, PPARg agonist, in mice with TIC injury to assess the attenuation of trigeminal neuropathic pain; and (3) systemic administration of PPARg antagonists to better determine whether PIO acts through PPARg-dependent pathways to attenuate orofacial neuropathic pain.
MATERIALS AND METHODS
All experimental procedures were performed in accordance with the guidelines provided by the National Institute of Health regarding the care and use of animals for experimental procedures. Animal protocols were approved by the University of Kentucky's Institutional Animal Care and Use Committee. All animals were housed in facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care International, and the US Department of Agriculture.
Animals
All experiments were performed with C57Bl/6 male, wild-type mice that weighed between 25 and 35 g purchased from Harlan Laboratories (Indianapolis, IN). Animals were randomly assigned to receive either experimental (TIC injury model) surgical procedures, sham surgical procedures, or to remain in the naive cohort. Mice were housed in a wellventilated mouse housing room (maintained at 20 to 221C) with a reversed 10/14 hours dark/light cycle so that testing could be performed in their active period. All mice had access to food and water ad libitum throughout the duration of the experiment. Low soybean content normal chow diet was provided (Teklab 8626; Harlan Laboratories).
TIC Surgery
Mice were anesthetized with sodium pentobarbital (70 mg/kg, intraperitoneally [ip]). With standard sterile surgery, the head was shaved, and ophthalmic cream applied over the eyes to protect them from overdrying. Mice were then fully constrained in a stereotaxic frame. A small 15 mm incision was made along the midline of the head and the conjunctiva of the orbit was opened along the top inner corner of the left eye bony socket with the tip of the surgical scalpel blade. Small cotton balls were used as tools in the orbital cavity for blunt tissue isolation and bleeding control. The infraorbital nerve was located approximately 5 mm deep against the maxillary bony infraorbital fissure in the orbital cavity. Animals randomly assigned to receive the TIC surgery underwent surgical placement of a 2 mm length of chromic gut suture , inserted between the infraorbital nerve and the maxillary bone infraorbital fissure. Chromic gut suture was inserted specifically in this region to adhere to specific infraorbital nerve bundles to prevent the chromic gut suture from sliding into the orbital cavity, but not to pierce the entire infraorbital nerve. Mechanical allodynia was induced in the mouse whisker pad ipsilateral to the surgery side due to the physical stimulation provided by the chromic gut suture against the nerve as well as the chromate salt released from the suture. Animals assigned to receive sham surgical procedures did not have the chromic gut suture placement, but only received the skin incision. Naive animals did not receive any surgery. All mice were aged matched. 36 One experimenter gently restrained the mouse in their palm (2 to 5 min) with a cotton glove until the mouse was acclimated and calm. A second experimenter applied the von Frey filaments to the mouse's whisker pad. The 0.16 g (3.22) fiber was applied first. If the mouse responded 3 or more times out of 5 trials to the fiber, this was considered to be a positive response and the next lower gram force filament was applied. However, if the mouse responded 2 or fewer times out of 5 to the fiber applied, this was recorded as a negative response and then the filament with the next higher gram force was applied. Head withdrawal/front paw sweeping/biting behaviors were considered positive responses. Time between applications of each filament was 2 to 10 seconds. After 1 fiber successfully caused positive responses, application of the subsequent fibers continued until 4 fibers were applied or until the threshold was established positive response to the lowest gram force fiber. Data were analyzed with a curve-fitting algorithm that allowed for estimation of the 50% mechanical withdrawal threshold (measured in gram force). The decreased mechanical threshold value is an index of mechanical allodynia. Responses to the von Frey fiber stimulations were recorded on day 7 after surgery (TIC and sham) and continued once a week postsurgery, testing both the ipsilateral and contralateral whisker pads. A cohort of naive mice was tested intermittently (weeks 2, 4, 8, 10, 11) alongside the sham animals and mice with TIC.
Detecting

Immunohistological Study
Mice with TIC injury, 3 weeks after injury, and agedmatched naive mice were anesthetized with isoflurane and perfused transcardially with heparinized saline followed by 4% ice-cold paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4) solution.
The brainstem was dissected and then placed in 4% paraformaldehyde in 0.1 M PB solution (pH 7.4) for overnight postfixation. This was followed by a 24-hour soak in 30% sucrose in PB. The brainstems were then embedded in OCT Compound (Tissue-Tek; Sakura, Torrance, CA) and sectioned with a cryostat at the thickness of 40 mm which were placed sequentially in 24-well plates filled with ethylene glycol-based antifreeze solution, stored at À 201C until immunohistological study. To insure the integrity of the stain and control for variability, tissue sections (9 to 12/each animal) from different groups were simultaneously processed on the same day. On the day of immunostaining, the tissue sections were floated to wash with 0.1 M phosphate-buffered saline (PBS, pH 7.4), and pretreatment with 3% hydrogen peroxide in 0.1 M PBS (pH 7.4) for 15 minutes to destroy endogenous peroxidase activity in erythrocytes. Tissue sections were then blocked using 0.5% Triton X-100 in PBS (15 min) to permeabilize cell membranes and reduce cell surface tension to increase the antibody penetration. Subsequent 5% normal goat serum in PBS (40 min) was used to block nonspecific antigen-antibody combinations. Sections were incubated overnight at 41C with rabbit polyclonal anti-PPAR-g immunoglobulin G (first antibody) (1:6000 dilutions, H-100; Santa Cruz Biotechnology Inc., Dallas, TX). The subsequent day, the sections were processed with a ABC Kit (Vectastain ABC Kit; Vector Laboratories Inc., Burlingame, CA) that is incubated at room temperature with a secondary bioatinylated goat anti-rabbit immunoglobulin G (1:200) for 40 minutes. The sections were then incubated with avidin-biotin complex reagent for 40 minutes. Finally, the antibody-antigen interaction was visualized with a peroxidase-catalyzed reaction. The sections were mounted onto Superfrost Plus glass slides which are electrostatic to attract frozen tissue sections (VWR MicroSlides; VWR International LLC, Radnor, PA). The slides were allowed to air dry for at least 4 hours before they were dehydrated through graded ethanol and xylene. The slides were
Image Analysis
The immunostaining intensity within the brainstem trigeminal sensory spV nucleus subnuclei (oralis, interpolaris, and caudalis) was analyzed from the digitized images (9 to 12 tissue sections/animal, n = 3) spaced at 400 mm intervals using ImageJ (1.46, National Institute of Health). Each subnucleus of the spV was identified as a region of interest and analyzed for mean fluorescent intensities. To identify PPARg immunoreactivity differences, each subnucleus of the complex was analyzed separately. The mean fluorescent intensities of the spV dorsal horn were measured in mice with TIC injury and then compared with that in naive mice.
Drug Preparation and Administration
Several PPAR agonists and antagonists were tested (see Table 1 for drug administration, doses, and actions). The PPARg agonist, PIO hydrochloride (Santa Cruz Biotechnology Inc.) was dissolved in normal saline followed by 30 seconds of vortexing. Then the solution was sonicated for 20 minutes before use. A PPARa agonist, bezafibrate (2-[4-[2-4-chlorobenzamidoethyl]phenoxy]-2-methylpropanoic acid; Sigma-Aldrich, St Louis, MO), was dissolved in 1% carboxymethyl cellulose and was vortexed for 30 seconds. Fenofibrate, PPARa agonist; GW0742, PPARb/d agonist and GW9662, PPARg antagonist (Cayman Chemical Company, Ann Arbor, MI) were dissolved in 10% dimethyl sulfoxide (Sigma-Aldrich) in saline and vortexed for 30 seconds before administration. All drugs were fresh prepared on the day just before administration.
Drugs were administered at least 8 weeks postoperation after mechanical allodynia was confirmed to determine the efficacy of each drug in the chronic neuropathic pain condition. All doses were chosen based on drug safety and efficacy reported in previous studies. 6, 25, 27, 28, [37] [38] [39] [40] [41] Pioglitazone was administered (ip) at doses of 100 and 300 mg/kg (< 10 mL/kg volume) with a 30 G/3/10 mL sterile insulin syringe (BD, Franklin Lakes, NJ). Lower doses of PIO (r100 mg/kg) have been reported in previous studies, but when no effect was observed at 100 mg/kg, doses were increased accordingly. For a mouse, the reported LD50 of PIO given systemically ranges from 181 to 1200 mg/kg, therefore the 600 mg/kg dose has been administered orally (US Pharmacopeial Convention, 2013). Oral gavage of 600 mg/kg was administered in a volume of <10 mL/kg with a stainless-steel curved oral gavage needle (22Â1.5 mm tip; Med-Vet International, Mettawa, IL). 42 The PPARa agonists, bezafibrate (100 mg/kg po; LD50 500 mg/kg) and fenofibrate (200 mg/kg ip; LD50 1200 mg/kg), and the PPARb/d agonist, GW0742 (1 mg/kg and/or 6 mg/kg ip) were given systemically to serve as PPAR activation controls. The LD50 of GW0742 has not been reported.
In a separate cohort of mice, the PPARg antagonist, GW9662 (30 mg/kg ip), was injected 30 minutes before the PPARg agonist, PIO (300 mg/kg ip) was given. This dose of PIO was chosen because it had the maximum effect on the elevation of mechanical threshold in TIC injury animals in our dose response study. GW9662 was used to block PIO from binding to PPARg as in previous studies. 6, 39, 43 During each drug testing, mechanical threshold was measured at time points of 0, 0.5, 1, 2, 3, 4 hours posttreatment on the ipsilateral whisker pad only. The 600 mg/kg oral dosing of PIO was tested for 6 hours because an attenuation effect was observed starting at the fourth hour postinjection time point. To increase in the numbers (n) in the treatment groups for these experiments, mice were tested with these drugs using the Latin square type crossover method with at least 1-week interval between each drug testing to allow sufficient time for the effect of a previous treatment to diminish. Vehicle for the PIO study was normal saline. For all other drugs, 10% dimethyl sulfoxide in saline was administered to the mice with TIC injury to serve as the vehicle. One experimenter was blinded to the drugs given to the animals for each experiment.
Statistical Analysis
Data were expressed as means ± SEM. The GraphPad Prism 6 statistical program was used for data analyses (Graph Pad Software Inc., La Jolla, CA). All behavioral data including drug studies were analyzed using a 2-way analysis of variance (ANOVA) with a Fisher post hoc test; histologic studies were analyzed by a 2-way ANOVA with a Tukey post hoc test (where is appropriate); Pr0.05 is considered significant.
RESULTS
Mice With TIC Injury Displayed Unilateral Whisker Pad Mechanical Allodynia
The baseline mechanical threshold was initially the same on both sides of the whisker pad of mice with/without TIC (3.51 ± 0.18 g for the left; 3.74 ± 0.45 g for the right). Mice with TIC injury experienced unilateral decreased mechanical threshold-an index of mechanical allodynia on the whisker pad ipsilateral to the surgery site within 1 week postsurgery lasting until the euthanasia day (week 14 postinjury). The mean 50% mechanical threshold of the ipsilateral whisker pad for the mice with TIC injury (0.24 ± 0.92 g) was significantly lower compared with that on the contralateral whisker pad (3.51 ± 0.18 g; n = 8; P < 0.0001, 2-way ANOVA, Fisher post hoc test, Fig. 1) . Also, the sham operation control mice did not demonstrate any changes in their mechanical threshold after surgery and were significantly different from whisker pad sensitivity associated with TIC nerve injury (3.51 ± 0.36 vs. 0.24 ± 0.92 g; n = 8; P < 0.0001, 2-way ANOVA, Fisher post hoc test).
Effect of PPAR Agonists on Mechanical Allodynia of Mice With TIC Injury
PPARc Agonist, Pioglitazone, Attenuated Mechanical Allodynia in Mice With TIC Injury
At 8 weeks post-TIC, PIO (300 mg/kg ip) effectively attenuated mechanical allodynia of the ipsilateral whisker pad. The mechanical threshold increased from 0.24 ± 092 g before drug treatment to 1.61 ± 0.54 g at hour 1, peaked at 2 hours (2.72 ± 0.74 g), and persisted for 3 hours (2.33 ± 0.98 g; Fig. 2A ). This was a significant increase in the threshold compared with the vehicle treated mice with TIC nerve injury (2.72 ± 0.74 vs. 0.10 ± 0.04 g; 2-way ANOVA, Fisher post hoc test, P < 0.0001; n = 3 to 7). Oral administration of PIO hydrochloride (600 mg/kg po) also attenuated mechanical allodynia in the mice with TIC injury (5 h: 0.87 ± 0.32 g; 6 h: 0.92 ± 0.45 g; 2-way ANOVA, Fisher post hoc test, P < 0.05; n = 3 to 7) compared with the saline treated mice with TIC injury (0.03 ± 0.00 g; 2-way ANOVA, Fisher post hoc test, P < 0.05; n = 3 to 7). This effect was significantly different at 5 and 6 hours after treatment. However, this dose was not as effective as the 300 mg/kg ip dose of PIO. The 100 mg/kg ip dose of PIO did not have an analgesic effect on the mice with TIC injury compared with saline-treated mice (0.56 ± 1.40 vs. 0.10 ± 0.04 g). The 300 mg/kg ip dose elicited hypothermic side effects that were most likely an indication that the dose was too high. However, the 100 mg/ kg intraperitoneal injection and 600 mg/kg oral doses did not elicit any observable overt side effects. These results suggest that PPARg receptor is a key player in whisker pad mechanical allodynia in the mice with TIC injury.
PPARb/d Agonist Moderately Attenuated Mechanical Allodynia in the Mice With TIC Injury
The administration of PPARb/d agonist, GW0742 (6 mg/kg ip), partially attenuated mechanical allodynia in mice with TIC injury compared with vehicle-treated mice with TIC injury. The effect peaked at 2 hours after injection (1.59 ± 0.55 vs. 0.06 ± 0.02 g; 2-way ANOVA, Fisher post hoc test; P < 0.0001, n = 4 to 6; Fig. 2B ). Administration of GW0742 1 mg/kg dose did not attenuate the mechanical allodynia (0.51 ± 1.31 g).
PPARa Agonist Had No Effect on the Mechanical Allodynia of Mice With TIC Injury
Two PPARa agonists were used in this experiment. Bezafibrate is a pan-PPAR agonist with the highest affinity for the a subunit. Bezafibrate at 100 mg/kg ip injection had no effect on mechanical allodynia in mice with TIC injury (treated: 0.55 ± 1.34 g vs. vehicle: 0.71 ± 1.52 g; 2-way ANOVA, Fisher post hoc test; P > 0.05, n = 3 to 6; Fig. 2C ). The second and more specific PPARa agonist, fenofibrate, was administered at 200 mg/kg ip with attenuation on mechanical allodynia (0.56 ± 1.28 g) not observed at this particular dose. These results demonstrated that activation of PPARa at these doses does not contribute to the attenuation of the mechanical allodynia in the mice with TIC injury.
PPARc Antagonist, GW9662, Blocked Analgesic Effects of Pioglitazone GW9662, a potent antagonist of PPARg, at the dose of 30 mg/kg (ip) successfully blocked the actions of PIO (300 mg/kg ip) in alleviating mechanical allodynia in mice with TIC injury (GW9662 + PIO: 0.53 ± 1.29 g vs. PIO only: 1.55 ± 1.41 g; 2-way ANOVA, Fisher post hoc test, n = 4 to 7; P < 0.0001, Fig. 2D ). These results provide evidence that PIO is acting through a PPARg-dependent mechanism to attenuate mechanical allodynia.
Increased PPARc Immunoreactivity in spV of Mice With TIC Injury
The entire trigeminal brainstem sensory spV nucleus was analyzed for PPARg immunoreactivity (mean intensities) in mice 3 weeks after TIC injury for comparison with naive controls. Although the PPARg-positive neurons were stained in both mice with TIC and naive mice, the PPARg-like immunoreactivity greatly increased in specific regions of the spV nucleus in the injured animals. Figure 3A shows the tissue sections through the entire spV in a naive mouse and in a mouse with TIC nerve injury. Higher power micrographs of tissue sections representing each level of the spV from a mouse with TIC nerve injury provide detail within spV at each level (Figs. 3B-E) . Figure 4 depicts the mean intensities of the immunoreactivity of PPARg throughout the spV in the mice with TIC injury compared with naive mice (n = 3 with 9 to 12 sections/ animal). There was significantly higher relative optical density for PPARg immunoreactivity in the spV of the mice with TIC However, PPARg immunoreactivity in the spinal trigeminal caudalis of the mice with TIC injury was greater than that of the other trigeminal spinal subnuclei and significantly different from oralis (P < 0.01) and interpolaris (P < 0.05; 2-way ANOVA, Fisher post hoc, n = 3 with 9 to 12 sections/ animal). Furthermore, there was a bilateral increase in PPARg immunoreactivity only in the spV caudal oralis in mice with TIC injury (ipsilateral: 65.43 ± 12.68, contralateral: 67.22 ± 10.89). Figure 5 illustrates the ipsilateral spinal trigeminal interpolaris in the mice with TIC injury compared with naive mice. Although PPARg immunoreactivity also appears in the spV of naive mice (A, B), the mean staining intensity was much less compared with that of the mice with TIC nerve injury (C, D). The white arrows indicate the nerve axonal projections of whisker barrels of spinal trigeminal zone that have been shown to correlate with the receptive fields on the whisker pads of the mice. 44 As indicated in this 20Â image, PPARg-positive neurons were primarily located at the sites indicated by the black arrows. PPARg also appears to be localized in very small nuclei consistent with previous findings of PPARg staining in glial nuclei. 6 . Pioglitazone (PIO) attenuated whisker pad mechanical allodynia in the mice with trigeminal inflammatory compression (TIC) injury. Hypersensitivity was attenuated by specific peroxisome proliferator-activated receptor (PPAR)-g agonism with (A) PIO rapidly elevating the 50% mechanical threshold in the mice with TIC at higher doses (300 and 600 mg/kg), but was ineffective at 100 mg/kg (n = 3 to 7). B, GW0742, PPARb agonist, attenuated mechanical allodynia in the mice with TIC injury at a dose of 6 mg/kg, but was not as effective as PIO (n = 4 to 6). C, PPARa agonists, bezafibrate and fenofibrate at indicated doses, were not effective in alleviating mechanical allodynia in the mice with TIC injury (n = 3 to 6). D, PPARg antagonist, GW9662, blocked the anti-allodynic effect of PIO at a dose of 30 mg/kg (n = 4 to 7). *P < 0.05, ****P < 0.0001; 2-way analysis of variance, Fisher post hoc test.
DISCUSSION
This study determined that PPARg plays a significant role in trigeminal mechanical sensitivity testing. Histologic images revealed that 3 weeks after TIC nerve injury intense PPARg immunoreactivity appeared in the spV caudalis compared with other subnuclei of the brainstem trigeminal dorsal horn where the primary nociceptive nerve fibers synapse onto second order neurons. Systemic administration of a PPARg agonist, PIO, attenuated the mechanical allodynia in mice with TIC nerve injury at doses of 300 mg/kg ip and 600 mg/kg po. The higher efficacy of the 300 versus 600 mg/kg dose is likely reflective of decreased bioactivity after gastric degradation. Differences in drug effect on pain-related behavior in the current study was reflective of the different routes of administration utilized. The LD50s for all drugs are shown in Table 1 . Administration of a PPARg antagonist, GW9662 (30 mg/kg ip) before the optimal dose of PIO (300 mg/kg ip) blocked the analgesic effect of PIO indicating that PIO is acting through a PPARg mechanism. Taken together, these results confirm PPARg's role in trigeminal pain transmission. Upon PPARg activation, reduced inflammation and reduction of neuropathic pain after an injury has also been reported that would also contribute to reduced pain-related behavior. 6 PPARg has been more thoroughly investigated than PPARb/d. Only a limited number of other studies have reported that PPARb/d agonists attenuate inflammatory pain. 45, 46 The biological role of PPARb/d has remained elusive due, in part, to its broad tissue expression and the lack of good chemical tools with which to study its physiologic function. However, the PPARb/d agonist, GW0742 had a minimal attenuation effect on the allodynia in the mice with TIC injury. The results showed that activation of PPARb/d isoform may play some role in the mechanical allodynia induced by the TIC nerve injury, but additional doses should be tested.
On the basis of the findings here, PPARg and PPARb/ d are potential therapeutic targets to inhibit transmission of pain, whereas PPARa does not appear to be a key player in trigeminal neuropathic pain. This is in contrast to a few controversial studies reporting PPARa activation has an inhibitory effect on nociception after nerve injury or inflammation. 6, 37, 47, 48 No study has reported PPARa activation eliciting an analgesic effect in trigeminal neuropathic pain. Likewise, the PPARa agonists, bezafibrate, and fenofibrate, had no effect on the allodynia in the present studies. However, use of higher doses of the 2 PPARa agonists may have increased the possibility of providing an analgesic effect in the mice with TIC injury.
It is well known that PPAR isoforms are widely expressed in adipose, liver, cardiac, endometrial stromal cells, immune cells, neurons, and glia of the peripheral and central nervous system. [9] [10] [11] [12] [13] [14] [15] [16] [17] Therefore, systemic administration of PIO will affect all PPARg receptors. In this paper, we wanted to show PPARg's presence in the trigeminal pain transmission pathway, specifically the trigeminal spinal nucleus caudalis, as this was the most likely site of action in reducing the hypersensitivity in the whisker pad region caused by the TIC surgery.
Moreno et al 32 previously reported PPARg in the dorsal horn of the brainstem and spinal cord. Maeda et al 49 confirmed Moreno findings as well as described localization in the sciatic nerve, dorsal root ganglia, and dorsal horn. These findings supported a role for PPARg in the somatic nociceptive pathway.
The present study revealed that PPARg immunoreactivity increases 3 weeks after the TIC nerve injury. This is consistent with the findings that PPARg is upregulated within weeks after other nerve injuries. 29, 31 In addition, our findings support previous studies demonstrating PPARg's presence in neuronal and glial cells. 6 Although this study identified PPARg immunoreactivity in putative neurons, future double-labeling experiments in spV with PPARg, neuronal, and glial markers (neuN, IB-4, OX-42) would serve as more conclusive evidence of PPARg's presence in neurons and/or glial cells, supporting its role in neurogenic inflammation.
PPARg activation has been shown to transrepress NF-kB thereby downregulating proinflammatory cytokines such as IL-6 and TNF-a. [6] [7] [8] 24, 50 Previous studies have reported that PPARg-deficient mice are more vulnerable to inflammatory diseases. [51] [52] [53] In our previous study, 35 we demonstrated microglial activation in the trigeminal dorsal horn of mice with TIC nerve injury. Therefore, one possible reason for the increase in PPARg immunoreactivity observed in the mice with TIC injury could be the inflammatory response occurring in the trigeminal dorsal horn. The upregulation of PPARg in the trigeminal nuclei likely indicates PPARg is activated to diminish the effects of the neuroglial immune system to counter or downregulate the proinflammatory cytokines.
Interestingly, PPARg immunoreactivity was most intense in the spV caudalis of the mice with TIC injury while barely detectable in naive mice. As the spV caudalis has been identified as the primary nucleus for transmission of nociceptive signaling, 3, 33, 54, 55 the increased expression might indicate why the PPARg receptor agonist, PIO, has analgesic effects on mechanical allodynia in mice with TIC injury. With the upregulation of PPARg, a stronger anti-inflammatory cell signaling effect could be initiated once PIO binds to its receptor.
However, there is much debate about the actions of PIO. Some scholars believe that PIO activates PPARg to induce transcription while others believe there are PPARg transcription-independent mechanisms occur to decrease allodynia. 6, 25, 39, 43, 56 Still, others suspect and have possibly demonstrated that PIO can act on other intracellular receptors such as acting on a mitochondrial membrane protein known as mitoNEET. 57 This would decrease cellular oxidative stress, a known initiator of chronic pain. 58 However, in present study, the block of PIO's analgesic actions by the PPARg antagonist, GW9662, leads us to suggest that PIO attenuates trigeminal nociception at least in part by acting through PPARg signaling. More studies need to be conducted to elucidate the action of PIO non-PPARg-dependent pathways. 
CONCLUSIONS
Overall this novel study determined that PPARg activation by PIO is a potential therapeutic target for treatment of orofacial neuropathic pain. The present study was not only the first to demonstrate that PPARg activation attenuates hypersensitivity induced in a trigeminal neuropathic pain model, but this is also the first study to identify PPARg immunoreactivity throughout the trigeminal brainstem sensory nucleus which increases after trigeminal nerve injury. Taken together, these studies provide information relevant to utilization of PIO as a potential treatment for patients with orofacial neuropathic pain. 
